The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials

Mathilda Skeie-Larsen (), Rebekka Stave, Janne Grønli, Bjørn Bjorvatn, Ane Wilhelmsen-Langeland, Amin Zandi and Ståle Pallesen
Additional contact information
Mathilda Skeie-Larsen: Department of Psychosocial Science, University of Bergen, 5007 Bergen, Norway
Rebekka Stave: Department of Psychosocial Science, University of Bergen, 5007 Bergen, Norway
Janne Grønli: Department of Biological and Medial Psychology, University of Bergen, 5007 Bergen, Norway
Bjørn Bjorvatn: Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, 5021 Bergen, Norway
Ane Wilhelmsen-Langeland: Bjørgvin District Psychiatric Center, Division of Psychiatry, Haukeland University Hospital, 5021 Bergen, Norway
Amin Zandi: Faculty of Psychology and Educational Sciences, University of Tehran, Tehran 1417935840, Iran
Ståle Pallesen: Department of Psychosocial Science, University of Bergen, 5007 Bergen, Norway

IJERPH, 2022, vol. 20, issue 1, 1-16

Abstract: Nightmares are highly prevalent and distressing for the sufferer, which underlines the need for well-documented treatments. A comprehensive literature review and meta-analysis of the effects of different pharmacological placebo-controlled randomized clinical trials, covering the period up to 1 December 2022, was performed. Searches were conducted in PubMed, Embase, Web of Science, PsychInfo, Cinahl, and Google Scholar, resulting in the identification of 1762 articles, of which 14 met the inclusion criteria: pharmacological intervention of nightmares, based on a placebo-controlled randomized trial published in a European language, reporting outcomes either/or in terms of nightmare frequency, nightmare distress, or nightmare intensity, and reporting sufficient information enabling calculation of effect sizes. Most studies involved the effect of the α 1 -adrenergic antagonist prazosin in samples of veterans or soldiers suffering from posttraumatic stress disorder. Other medications used were hydroxyzine, clonazepam, cyproheptadine, nabilone, and doxazosin. The vast majority of studies were conducted in the USA. The studies comprised a total of 830 participants. The Clinician-Administered PTSD Scale was the most frequently used outcome measure. The results showed an overall effect size of Hedges’ g = 0.50 (0.42 after adjustment for publication bias). The synthetic cannabinoid nabilone (one study) showed the highest effect size ( g = 1.86), followed by the histamine H 1 -antagonist hydroxyzine (one study), and prazosin (10 studies), with effect sizes of g = 1.17 and g = 0.54, respectively. Findings and limitations are discussed, and recommendations for future studies are provided.

Keywords: nightmare; pharmacological intervention; RCT; meta-analysis; PTSD (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/1/777/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/1/777/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2022:i:1:p:777-:d:1021650

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().